Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent progress.
Buy time for me again. Far too many positive catalysts not to.
At this phase I cannot imagine being without a Revive-heavy (investments) weighting. It has been a long, bumpy ride as many of the long term investors here will attest to however, I / we do believe we are on the cusp of greatness. Very, very exciting time to be a Revive investor. What a truly excellent entry moment for new investors too.
Agreed. Palmer comes across as a tactless numpty frankly.
150%
Bought a lot more in the past 24 hours or so. I believe Solana's future is very, very bright indeed.
Not concerned by Ryoshi's social media stunt. Nor are our Whales.
“I am not important, and one day I will be gone without notice. Take the SHIBA and journey upwards frens.” @RyoshiResearch
Excellent. Highly encouraged and very excited for Revive & Bucillamine.
Tripled my SOL holding this week. Far too attractive not to at this price and SOL's increasing credibility.
Precisely, Rick. SHIB is unquestionably a special one among a large pool of mostly rubbish. Personally I am adding regularly and holding everything.
Even you with your post history can no longer credibly defend this stock investment. I have held on for 3+ years and it has done nothing to boast about. Hover around the $2 mark has been the constant theme. Be honest and recognizant vs spouting your blind desperation constantly.
SHIB is validated here. The future is bright for SHIB IMO.
The risk with this scenario is big pharma ‘bully’ literally (pro rata) swaps (converts) their currently-valued shares for Revive’s current market cap making Revive’s CEO lots of money based on his share count- while we long term investors get sweet FA based on missed multiple X value. Organic growth / success is highly preferable in my opinion. Or a massive entire acquisition scenario. We want multiple XXX returns vs pro rated shares in e.g. Pfizers current market cap.
It is buy time for me again. Loving this market dip ($$$ opportunity) personally. GL SHIB Army.
Much excitement and anticipation for Revive's pending success across the internet right now. Pleased I added to my investment earlier this week.
Excellent.
Excellent.
Added a ton in anticipation of making a ton+ of profit. A no-brainer strategy for me down here personally. GL.
Amused to read all the negatives while the entire Crypto space is in the toilet (for now). BUYING BUYING and MORE BUYING is what one should be doing right now down here IMO. Easy decisions.
MindMed Appoints Schond L. Greenway as Chief Financial Officer
NEW YORK, May 23, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.
“We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech capital markets, which was a key attribute we sought in identifying a CFO,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “Schond is joining MindMed at an exciting point in our growth, with numerous near-term milestones ahead across our pipeline. I look forward to working closely with him to advance our mission of becoming a global leader in the development of innovative therapies for brain health disorders.”
“This is an exciting time to be joining the Company as it continues its patient-focused mission of developing innovative new therapies to improve outcomes for individuals with anxiety, addiction and autism,” said Mr. Greenway. “I’m excited to join this dynamic and talented team. I look forward to working with the management team to advance the Company’s robust pipeline and contribute to its success.”
Mr. Greenway joins MindMed after serving as CFO of Avalo Therapeutics, a precision medicine clinical stage biopharmaceutical company. He previously served as VP of Investor Relations at Mesoblast, an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. and in various roles at investment banking firms Morgan Stanley and Barclays Capital, predominantly focused on healthcare and technology. Mr. Greenway has participated in and advised on numerous transactions during his tenure in investment banking and capital markets. He has assisted in securing significant cumulative growth capital through a variety of equity and debt instruments in the public and private markets, as well as through funding from significant collaboration arrangements with therapeutics companies.
Mr. Greenway received an MBA from the Darden Graduate School of Business – University of Virginia and a BS from Florida A&M University.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
I'm buying here. Covid is not going away anytime soon and Revive's exposure is increasing.
We prefer organic success / growth vs most buy-out scenarios. The latter typically converts PPS equivalents with no real $ gain. The exception is Big Pharma paying multi-billions for the whole RVVTF shooting match in a one swoop transaction which would be highly $ for all plus us shareholders. Interesting times for us long time shareholders. CEO Mike ought to stand up and be counted now. If he screws us shareholders per se, he may never sleep well again IMO.
Excellent progress by MindMed. Very promising indeed.
Strong post and thank you for all your regular contributions too. SHIB's increased value shall prevail given time. Very excited to be buying more SHIB at these levels. What an incredible opportunity.
Excellent.
Warren Buffet has made his fortune buying during crashes like this and at lows. He buys when most others are panicking and running for the hills. That was the point I was making. As a side comment, I don't think he is known as crypto fan at this time, no.
Added 2.4 Billion so far this week. Easy decision for me personally. Gl all and ride out the market turbulence if you have the strength (down here is an excellent $ opportunity given historical patterns plus Warren Buffet's investing general philosophy).
Excellent.
Added 435M SHIB over the past 2 days. Riding the storm and taking full advantage!
Agreed. Exceptional loading & entry point here. Big future for Khiron..I do like Alvaro our CEO and believe he will see his shareholders right moving forward. His father is a successful executive too so that is a healthy dynamic in our favor.
This is HUGE.
Precisely. When whales buy, I BUY (MORE). Simple decision.
I am buying here personally. GL all.
I would think $1 is easily possible. I have hopes for far higher - especially once Elon starts sending Doge rockets to Space plus he is set to own Twitter.
Excellent.
Such a legitimate need and place for Revive's (patented) Bucillamine in the medical world.
Well said and we concur. Loading time here again for me*
Incredible buy price here. Selling some other stocks and loading up again on MindMed. Easy decision based on my faith in this space and MindMed's cash position, pipeline and leadership team.
Nice buy at that price! Still have high hopes and expectations for Dr Sen to leverage his pioneering technology! He owes us Longs way more than he is providing as our CEO.